A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

ClinicalTrials.gov ID: NCT00279422

Public ClinicalTrials.gov record NCT00279422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.

Study identification

NCT ID: NCT00279422
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Facet Biotech; Industry
Enrollment: 127 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

visilizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2006 (Type not available)
Primary completion: Aug 2007 (Actual)
Completion: Aug 2007 (Actual)
Last update posted: Mar 12, 2012

2006 – 2007

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Los Angeles	California	90048	—
Not listed	San Francisco	California	94115	—
Not listed	Gainesville	Florida	32608	—
Not listed	Tampa	Florida	33606	—
Not listed	Atlanta	Georgia	30342	—
Not listed	Macon	Georgia	31201	—
Not listed	Chicago	Illinois	60637	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Lexington	Kentucky	40536	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Rochester	Minnesota	55905	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029	—
Not listed	Pittsburgh	Pennsylvania	—	—
Not listed	Charleston	South Carolina	29425	—
Not listed	Nashville	Tennessee	—	—
Not listed	Galveston	Texas	77555-0764	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00279422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 12, 2012 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00279422 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →